Inhibiting retrotransposon and retroviral integration by targeting the atm pathway
CA 2414017 A1 · Owner: Lau, Alan · Inventors: Lau, Alan; O' Connor, Mark James; Jackson, Stephen Philip
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Ataxia telangiectasia mutated (ATM)-dependent DNA damage signalling mechanisims are involved in retroviral and retrotransposon integration. Screening methods for inhibitors of retroviral and retrotranspons activity comprise inhibiting the ATM-dependent DNA damage signalling pathway e.g. by , disrupting interaction between components of the pathway. Inhibitors are useful as anti-retroviral agents, e.g. in inhibition of HIV.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.